@NatureCancer

Nature Cancer is a journal dedicated to publishing the latest advances across all areas of cancer research.

 New York, USA
nature.com/natcancer
Joined January 2019
  • Tweets2K
  • Following372
  • Followers40.1K
544Media
📢Our September Issue is out! Read about generative AI for digital pathology, cancer immunometabolism, GITR antibody optimization, l-glutamine combination therapy, and more 🔗nature.com/natcancer/volumes…
2
6
15
2,242
Attending #ESMO26? Our Senior Editor, @Vin_Giacco, will be there and looks forward to connecting with the oncology community. Get in touch to discuss your latest research and publishing opportunities at Nature Cancer.
Vincenzo Giacco, PhD@Vin_GiaccoOct 14
Looking forward to attending the #ESMO26 Annual Meeting in Madrid! I'll be there representing @NatureCancer and meeting the oncology community. Happy to discuss your latest research, publishing opportunities, or ideas for the journal, please reach out. See you in Madrid 🇪🇸
3
1,325
🧬New in Nature Cancer: The phase 2 PEGASUS trial explores a ctDNA-guided strategy to de-escalate or escalate adjuvant therapy in patients with high-risk stage II and stage III colon cancer, moving us closer to more personalised treatment decisions. nature.com/articles/s43018-0…

Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II...

Nature Cancer - Marsoni et al. evaluated the feasibility of a dynamic circulating tumor DNA-guided adjuvant and postadjuvant treatment strategy in patients with resected microsatellite-stable,...

nature.com
3
3
1,402
📢Read our Series on Next-generation cancer therapeutics featuring commissioned Reviews and a selection of articles published in Nature Cancer! nature.com/collections/hehde…

Series on Next-generation cancer therapeutics

We introduce our Series on Next-generation cancer therapeutics with commissioned Reviews, Perspectives and opinion pieces on the latest advances in targeted ...

nature.com
1
1
1,434
🚨New in Nature Cancer Dr Gong and colleagues report findings from the phase 1 study evaluating L-glutamine + gemcitabine/nab-paclitaxel in untreated advanced PDAC. ORR 44%, including 12.5% CR, with median OS of 22 months. #PancreaticCancer @jgong15 nature.com/articles/s43018-0…

l-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic...

Nature Cancer - In this open-label, single-arm, phase 1 GlutaPanc trial, Gong and colleagues report the safety and feasibility of l-glutamine in participants with advanced pancreatic ductal...

nature.com
3
1
7
3,254
Now Online! The neuropeptide galanin impairs antitumor immunity in glioblastoma by interacting with its receptor GALR3 on monocytic myeloid-derived suppressor cells, promoting their infiltration and ferroptosis resistance. nature.com/articles/s43018-0…

Galanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance...

Nature Cancer - Chen and colleagues report that the neuropeptide galanin impairs antitumor immunity in glioblastoma by interacting with its receptor GALR3 on monocytic myeloid-derived suppressor...

nature.com
1
6
25
3,574
Our August issue is live!🏖️ Featuring copper dependency in AML, iron-mediated ferroptosis, GPNMB-directed CAR-T cell therapy, IDH1-mutant vaccine in phase 1 trial, and more 🔗nature.com/natcancer/volumes…
2
5
19
2,297
The full agenda for Reframing Precision Medicine is now live. We created this event with the goal of moving medicine beyond theory to show how multi-omics, AI, and big data can make truly personalised care the norm. Join us in London: invt.io/1txbmzq1h21

Reframing Precision Medicine: Innovation to Implementation 2026,

View final agenda

invt.io
3
4
1,648
💫Online today The Review on intratumor heterogeneity by @Jonathancmwan, @NickyMcGranahan and @CharlesSwanton 🔗nature.com/articles/s43018-0… Check out the rest of the Series on Tumor Heterogeneity and Plasticity here: nature.com/collections/gfbbj…

Charting intratumor heterogeneity from bench to bedside

Nature Cancer - Swanton and colleagues provide an overview on intratumor heterogeneity and cancer evolution arising from genetic factors and non-genetic regulation of cancer cells, the tumor...

nature.com
2
53
2
123
12,603
Nature Cancer retweeted
Nature Conferences@NatureConfAug 4
Join @NancyFGoodman, @Gilles_Vassal and 15 other global experts at our event with @StJudeResearch, looking to address urgent challenges and opportunities in childhood cancer care. Secure a seat and submit an abstract by Aug 6. go.nature.com/4sT18WF
5
1
4
3,641
☀️Check out our July issue ! ✅Tertiary lymphoid structures ✅DNA vaccine for GBM ✅CAR T cell therapy in lung metastases ✅adjuvant chemotherapy in nasopharyngeal carcinoma ✅neutrophil-driven contact-dependent immune suppression ✅GABA in GBM nature.com/natcancer/volumes…
1
6
2
14
2,425
🌟Online today A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages nature.com/articles/s43018-0…
3
11
1
25
3,343
Nature Cancer retweeted
Tullia Bruno, PhD@BcellBrunoJun 19
Great week for the Bruno lab for publications. Check out our new commentary on #TLS in @NatureCancer @PittTweet @UPMCHillmanCC nature.com/articles/s43018-0…
11
39
2,810
In first-in-human phase 1 NOA16 trial, Platten and colleagues report the long-term clinical and immunological follow-up outcomes of a vaccine targeting mutant IDH1 in persons with astrocytoma. @Platten_lab nature.com/articles/s43018-0…

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm,...

Nature Cancer - In the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial, Platten and colleagues report the long-term clinical and immunological follow-up outcomes of a...

nature.com
7
22
3,360
🌻Check out our June issue ! ✅Metastatic dissemination in CRC ✅Immunotherapy in GBM ✅BH3 mimetics sensitization in AML ✅ctDNA and PSA to monitor prostate cancer ✅Methylation-based CNS tumor classification and more nature.com/natcancer/volumes…
5
24
3,217
Zemp at al. found GPNMB as a targetable antigen for MiT/TFE-family fusion-driven soft-part sarcoma and translocation RCC and tested GPNMB-directed CAR T cell therapy in preclinical models and in first-in-human trial. Read the N&Vs: nature.com/articles/s43018-0… nature.com/articles/s43018-0…

GPNMB-directed CAR-T cell therapies for solid tumors

Nature Cancer - Target discovery remains a considerable challenge in the development and translation of chimeric antigen receptor (CAR)-T cell therapies for solid tumors. Two reports in Nature and...

nature.com
12
27
3,455
🚨Check out our last release Bayik and colleagues show that inhibition of GABBR signaling extends survival in female glioblastoma models, highlighting the potential for sex-specific cancer treatments and the unique immune landscape shaped by GABA nature.com/articles/s43018-0…

GABA signaling activation drives glioblastoma progression in female mice through myeloid-derived...

Nature Cancer - Pathak et al. unveil a female vulnerability for glioblastoma according to a mechanism that relies on γ-aminobutyric acid receptor-mediated signaling on granulocytic...

nature.com
1
9
20
2,533
⭐️Online now Iron level and ferroptosis impair antitumor efficacy of CAR-T cells. by Dongrui Wang, Yongxian Hu, Pengxu Qian, He Huang & colleagues nature.com/articles/s43018-0…
17
42
3,118
📢Online now! @MoritzGerstung, Felix Sahm & co developed an AI algorithm that leverages H&E slides to classify central nervous system tumors into methylation-based subtypes reducing turnaround time to 12 min in prospective evaluation. nature.com/articles/s43018-0…

Hetairos is a histology-based artificial intelligence model for predicting central nervous system...

Nature Cancer - Jin et al. developed an artificial intelligence tool that leverages histology to predict methylation-based central nervous system tumor subtypes and validated it for tumor...

nature.com
6
28
2,639
⭐️Now online In a large cohort of patients with ICB-treated glioblastoma, Catherine J. Wu & colleagues show that baseline mesenchymal transcriptional state predicts therapy response, and transition to non-mesenchymal state results in acquired resistance. nature.com/articles/s43018-0…

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma

Nature Cancer - In a large cohort of participants with immune-checkpoint-blockade-treated glioblastoma, Ghannam et al. show that baseline mesenchymal transcriptional state predicts therapy response...

nature.com
1
16
37
4,019
Load more